Tag Archives: leaving

WCLC: Roche’s Tecentriq comes up short in squamous lung cancer, leaving Merck’s Keytruda ‘unchallenged’

Roche has been hoping its Tecentriq could put up the kind of life-lengthening numbers in squamous non-small cell lung cancer (NSCLC) that could help it compete with Merck’s Keytruda—but no dice. The Swiss drugmaker Tuesday unveiled results showing that its Tecentriq-chemo combo failed to outdo solo chemo at extending the lives of previously untreated patients.… Read More »